AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
Business Wire•07/08/2026•16:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.